Weekly Spotlight - 07.11.24

Community

We want to hear your story!

Fill in the form to share your experiences and any challenges you’ve faced living with your condition, for a chance to be featured in one of our weekly newsletters!

In the News

Ventus Therapeutics Announces Positive Phase 1 Trial Results for Investigational Drug VENT-03 for Lupus

Ventus Therapeutics has completed a successful phase 1 trial for VENT-03, an oral drug for lupus. The trial showed VENT-03 is safe, well-tolerated, and effective in inhibiting its target. Plans for a phase 2 study in 2025 are underway, offering hope for lupus patients.

ELF1 as a Biomarker for Disease Activity and Renal Involvement in Systemic Lupus Erythematosus

ELF1 is identified as a promising biomarker for systemic lupus erythematosus (SLE), offering hope for better diagnosis and treatment. The study highlights ELF1's potential in assessing disease activity and renal involvement, paving the way for future therapeutic research. This discovery brings optimism to SLE patient care.

GSK Set to Acquire CMG1A46 from Chimagen Biosciences

GSK is acquiring CMG1A46 from Chimagen Biosciences to boost its immunology portfolio, focusing on autoimmune diseases like lupus. The deal includes a £300 million upfront payment, with potential for £550 million more. CMG1A46, targeting B cell depletion, is in early trials for blood cancer and lupus.

Lupus Research Highlights at ACR Convergence 2024

The Lupus Research Alliance will present 33 studies at ACR Convergence 2024, showcasing advancements in lupus research. Highlights include new treatments and therapies, such as CAR T cell therapy and dapirolizumab pegol. The event underscores progress in understanding and treating lupus, offering hope to patients and families.